A Two-part, Randomized, Placebo Controlled, Double Blind, Multicenter, Phase 3 Study to Evaluate the Efficacy and Safety of Linerixibat for the Treatment of Cholestatic Pruritus in Participants With Primary Biliary Cholangitis (PBC)
Latest Information Update: 15 Jul 2024
At a glance
- Drugs Linerixibat (Primary)
- Indications Primary biliary cirrhosis; Pruritus
- Focus Registrational; Therapeutic Use
- Acronyms GLISTEN
- Sponsors GlaxoSmithKline; GlaxoSmithKline Research & Development; GSK
- 01 Jul 2024 Planned End Date changed from 8 Jan 2025 to 6 Jan 2025.
- 03 Jun 2024 Planned initiation date changed from 29 Jul 2021 to 28 Oct 2024.
- 03 Jun 2024 Status changed from recruiting to active, no longer recruiting.